Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

The impact of the PCSK-9/VLDL-Receptor axis on inflammatory cell polarization.

Tytuł:
The impact of the PCSK-9/VLDL-Receptor axis on inflammatory cell polarization.
Autorzy:
Barcena ML; Department of Medicine - Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Geriatrics and Medical Gerontology, Germany; DZHK (German Centre for Cardiovascular Research), Berlin Partner Site, Berlin, Germany.
Estepa M; Department of Medicine - Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany.
Marx L; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Geriatrics and Medical Gerontology, Germany.
Breiter A; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Geriatrics and Medical Gerontology, Germany.
Haritonow N; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Geriatrics and Medical Gerontology, Germany.
Stawowy P; Department of Medicine - Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Berlin Partner Site, Berlin, Germany. Electronic address: .
Źródło:
Cytokine [Cytokine] 2023 Jan; Vol. 161, pp. 156077. Date of Electronic Publication: 2022 Nov 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: <2001- > : Oxford : Elsevier Science Ltd.
Original Publication: [Philadelphia, PA] : Saunders Scientific Publications, W.B. Saunders, [c1989-
MeSH Terms:
Proprotein Convertase 9*/genetics
Leukocytes, Mononuclear*
Humans ; Lipopolysaccharides ; Tumor Necrosis Factor-alpha ; Lipoproteins ; Anti-Inflammatory Agents
Contributed Indexing:
Keywords: Atherosclerosis; Inflammation; PCSK9; THP-1 cells; VLDL-R
Substance Nomenclature:
EC 3.4.21.- (Proprotein Convertase 9)
0 (Lipopolysaccharides)
0 (Tumor Necrosis Factor-alpha)
0 (Lipoproteins)
0 (Anti-Inflammatory Agents)
EC 3.4.21.- (PCSK9 protein, human)
Entry Date(s):
Date Created: 20221110 Date Completed: 20221128 Latest Revision: 20230212
Update Code:
20240104
DOI:
10.1016/j.cyto.2022.156077
PMID:
36356495
Czasopismo naukowe
Background: Studies have shown that lipoproteins, such as LDL and VLDL, as well as its major protein component ApoE2 impact on macrophage polarization important in atherosclerosis. Proprotein convertase subtilisin/kexin 9 (PCSK9) is a key regulator of lipoprotein receptor expression. The present study investigated the effect of the VLDL/VLDL-receptor (VLDL-R) axis on mononuclear cell polarization, as well as the role of PCSK9 and PCSK9 inhibitors (PCSK9i) within this network.
Methods: Human monocytic THP-1 cells and human monocyte-derived macrophages isolated from peripheral blood mononuclear cells (PBMC) were treated with either LPS/IFN-γ to induce a pro-inflammatory phenotype, or with IL-4/IL-13 to induce an anti-inflammatory phenotype. Cells were then subjected to further treatments by lipoproteins, PCSK9, PCSK9i and lipoprotein receptor blockers.
Results: LPS/IFN-γ treatment promoted a pro-inflammatory state with an increased expression of pro-inflammatory mediators such as TNF-α, CD80 and IL-1β. VLDL co-treatment induced a switch of this pro-inflammatory phenotype to an anti-inflammatory phenotype. In pro-inflammatory cells, VLDL significantly decreased the expression of pro-inflammatory markers e.g., TNF-α, CD80, and IL-1β. These effects were eliminated by PCSK9 and restored by co-incubation with a specific anti-PCSK9 monoclonal antibody (PCSK9i). Migration assays demonstrated that pro-inflammatory cells displayed a significantly higher invasive capacity when compared to untreated cells or anti-inflammatory cells. Moreover, pro-inflammatory cell chemotaxis was significantly decreased by VLDL-mediated acquisition of the anti-inflammatory phenotype. PCSK9 significantly lessened this VLDL-mediated migration inhibition, which was reversed by the PCSK9i.
Conclusion: VLDL promotes mononuclear cell differentiation towards an anti-inflammatory phenotype. PCSK9, via its capacity to inhibit VLDL-R expression, reverses the VLDL-mediated anti-inflammatory action, thereby promoting a pro-inflammatory phenotype. Thus, PCSK9 targeting therapies may exert anti-inflammatory properties within the vessel wall.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2022 Elsevier Ltd. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies